NEW YORK ( TheStreet) -- Health care company Covidien ( COV) is falling in early trading on Thursday even though its earnings beat Street expectations.

Covidien experienced a 6% drop in sales of its pharmaceuticals versus the prior year, even as sales of its medical devices rose 6%. Medical supply sales declined 3%.

There has been a negative tenor throughout the health-care earnings season to this point, with fears about the macroeconomic conditions in the U.S. and Europe weighing on health-care company shares. In particular, drug sales into Europe have been a key point of concern as investors fear a continued European push to cut health care spending. The U.S. employment scenario and lower volume of patient business also continues to be a big concern.

Covidien earned 85 cents a share, five cents above the Street consensus. Profit of $364 million was ahead of the third quarter last year, when profit came in at $281 million.

-- Written by Eric Rosenbaum from New York.
Covidien Stock Rating Report
(COV) Rating and Financial Analysis

RELATED STORIES:

Follow TheStreet.com on Twitter and become a fan on Facebook.

Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

More from Stocks

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes